Gene Logic Inc has entered into a multi-year agreement with the National Institute on Drug Abuse (NIDA), an institute of the National Institutes of Health (NIH), to provide preclinical safety and pharmacology studies focused on one of NIDA's core research areas of interest-developing safe and effective medications for the treatment of drug addiction.

This project has been funded in whole with Federal funds from the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN271200488411C. The project provides for Gene Logic to achieve up to $6.0 million in revenue over the next four years based on specific studies and services requested by the agency over the life of the agreement. In turn, NIDA gains access to a resource for developing safety data on selected compounds that have already demonstrated efficacy in animal models, according to a Gene Logic release.

"Gene Logic increasingly is establishing itself as a differentiated and valued contract service provider to pharmaceutical companies and Federal agencies focused on areas of key concern to the nation's health," commented Mark D. Gessler, chairman and CEO of Gene Logic Inc.